Dianthus Therapeutics Inc.

Dianthus Therapeutics reported second-quarter 2026 results on August 4, highlighting a 75% response rate in an interim analysis of its Phase 3 CAPTIVATE trial for claseprubart in chronic inflammatory demyelinating polyneuropathy, surpassing the 50% bar. The company also completed enrollment in its Phase 2 MoMeNtum trial for multifocal motor neuropathy at 46 patients, above the target of 36, with top-line results expected in December. Net loss widened to $50.2 million from $31.6 million a year earlier, while research and development spending rose to $48.7 million from $26.3 million. Dianthus holds about $1.2 billion in cash, funding operations into 2030, and added a new pipeline candidate, DNTH312, with Phase 1 readiness targeted by end of 2027. The company also received Orphan Drug Designation for claseprubart in myasthenia gravis and began its Phase 3 EMERGE trial in June, with results not expected until the second half of 2028.

The chronic inflammatory demyelinating polyneuropathy treatment market is projected to grow positively by 2036 across leading markets, driven by an expanding diagnosed patient population, improved disease awareness, and the anticipated introduction of novel mechanism-based therapies. The United States accounted for the largest market size in 2025 compared with the EU4 countries, the United Kingdom, and Japan. Key companies advancing new treatments include Sanofi, Immunovant, argenx, Nuvig Therapeutics, Dianthus Therapeutics, and Takeda, with promising pipeline therapies such as Riliprubart, Batoclimab, Empasiprubart, NVG-2089, DNTH103, TAK-881, and TAK-411. The prevalence of CIDP is estimated at around 5 to 7 cases per 100,000 individuals in the UK, and the market is seeing increased demand for targeted and long-acting therapies including subcutaneous immunoglobulin formulations and FcRn inhibitors.

Dianthus Therapeutics shares have surged 88.9% over the past six months, driven by growing investor confidence in its lead asset claseprubart and a strong financial position. The company plans to initiate a pivotal phase III EMERGE study for generalized myasthenia gravis in 2026, with top-line data expected in the second half of 2028, and claseprubart recently achieved an early GO decision in the phase III CAPTIVATE study for chronic inflammatory demyelinating polyneuropathy. A phase II MoMeNtum study in multifocal motor neuropathy remains on track for top-line results in the fourth quarter of 2026. Dianthus also advanced its second candidate, DNTH212, into a phase I study in December 2025, with initial data expected in the second half of 2026. The company raised approximately $719 million in gross proceeds in March and held about $1.2 billion in cash, equivalents, and investments as of March 31, 2026, expected to fund operations into 2030.